SAGA Diagnostics
Biotechnology ResearchUnited States51-200 Employees
SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.
Innovative Liquid Biopsies SAGA Diagnostics specializes in ultrasensitive, multi-cancer MRD detection and bespoke digital PCR assays, positioning it as a leader in non-invasive cancer monitoring—offering opportunities to collaborate with hospitals and clinics adopting advanced precision oncology tools.
Recent US Market Entry The launch of SAGA's multi-cancer MRD platform and the commercial debut of Pathlight in the US suggest imminent growth in customer base; strategic sales outreach can target research centers and oncology practices eager for early detection solutions.
Partnership & Customization Strong partnerships with organizations like Medicon Village and AstraZeneca highlight SAGA’s ability to develop tailored assays; prospects exist for joint ventures or custom assay services with biomedical R&D firms and diagnostic developers targeting personalized cancer therapies.
Investments & Growth With $20 million in funding and a focus on innovation, SAGA is well-positioned to expand its product offerings; engaging with venture capital-backed biotech firms seeking advanced genomic testing solutions offers additional sales channels.
Recent Leadership and Innovation The appointment of a new CEO and ongoing assay development initiatives reflect a growth-oriented strategy; leveraging this momentum, sales efforts can target high-value clients interested in cutting-edge genomic diagnostics and future-proof cancer testing technologies.
SAGA Diagnostics uses 8 technology products and services including QuickBooks, GitHub, WordPress, and more. Explore SAGA Diagnostics's tech stack below.
| SAGA Diagnostics Email Formats | Percentage |
| First.Last@sagadiagnostics.com | 50% |
| First.Last@sagadiagnostics.com | 50% |
Biotechnology ResearchUnited States51-200 Employees
SAGA Diagnostics is a personalised cancer medicine and disease monitoring company focused on molecular genetic analyses of circulating tumor DNA and tissue biopsies.
SAGA Diagnostics has raised a total of $20M of funding over 3 rounds. Their latest funding round was raised on Jun 29, 2021 in the amount of $12Mas a Series A.
SAGA Diagnostics's revenue is estimated to be in the range of $25M$50M
SAGA Diagnostics has raised a total of $20M of funding over 3 rounds. Their latest funding round was raised on Jun 29, 2021 in the amount of $12Mas a Series A.
SAGA Diagnostics's revenue is estimated to be in the range of $25M$50M